Dermata Therapeutics Inc (DRMA) - Total Liabilities
Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has total liabilities worth $1.83 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Dermata Therapeutics Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Dermata Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Dermata Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Dermata Therapeutics Inc asset portfolio.
Dermata Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Dermata Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trajano Iberia Socimi SA
MC:YTRA
|
Spain | €85.60 Million |
|
APC Minerals Ltd
AU:APC
|
Australia | AU$422.25K |
|
Predilife
PA:ALPRE
|
France | €7.12 Million |
|
Ambica Agarbathies & Aroma industries Limited
NSE:AMBICAAGAR
|
India | Rs1.32 Billion |
|
Ambertech Ltd
AU:AMO
|
Australia | AU$30.93 Million |
|
Fluicell AB
ST:FLUI
|
Sweden | Skr6.56 Million |
|
OurLiving AB
ST:OURLIV
|
Sweden | Skr8.99 Million |
|
Austin Metals Ltd
AU:AYT
|
Australia | AU$201.35K |
Liability Composition Analysis (2019–2025)
This chart breaks down Dermata Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Dermata Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dermata Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dermata Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Dermata Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.64 Million | -16.85% |
| 2024-12-31 | $1.97 Million | +21.51% |
| 2023-12-31 | $1.62 Million | +75.98% |
| 2022-12-31 | $922.63K | -39.17% |
| 2021-12-31 | $1.52 Million | -59.91% |
| 2020-12-31 | $3.78 Million | +66.23% |
| 2019-12-31 | $2.28 Million | -- |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in… Read more